Abstract:
The present invention relates to a method for treating cancer in a subject by modulating MEX-3, by administering to said subject a therapeutically effective amount of a modulator of MEX-3.
Treating cancer by modulating MEX-3

Field of the Invention
The present invention relates to a method of treating cancer by modulating MEX-3. Alternatively, the antibody can inhibit the interaction between of MEX-3 and one of its partners.

Background of the Invention
Cancers and malignant tumors are characterized by continuous cell proliferation and cell death and are related causally to both genetics and the environment. Genes whose expression are associated with cancer, and the products of said genes, are of potentially great importance as cancer markers in the early diagnosis and prognosis of various cancers, as well as potential targets in cancer treatment. Cancer is the a leading cause of human death next to coronary disease. In the United States, cancer causes the death of over half-million people each year and about two million new cases of cancer are diagnosed each year. The identification of new genes essential for the growth of tumors has been an objective of cancer research over the past several decades.

In their C. elegans-based experimental model, the present inventors surprisingly found that MEX-3 interacts with the mRNA encoding CKI-2 and prevents expression of CKI-2 protein. MEX-3 is conserved in mammals and the mammalian homologues of CKI-2 are p21, p27 and p57, which are well-known tumour suppressors. Without wishing to be bound by theory, the inventors hypothesized that in human a regulation of expression of the tumour suppressors p21, p27 and/or p57 by any of MEX-3A/B/C/D could be important in cancer. Searches in different databases indicated that, indeed, MEX-3 is up-regulated in cancerous tissues and that the administering of carcinogens also up-regulates MEX-3 expression.

Summary of the invention
The present invention hence provides a method for treating cancer in a subject by modulating MEX-3 via the administration of a therapeutically effective amount of a modulator of MEX-3 to said subject. In some embodiments, MEX-3 is modulated by an inhibitor, such as an antibody. Alternatively, the inhibitor decreases or silences the expression of MEX-3, and is for instance a siRNA. In some embodiments, the subject is a mammal, for instance a human subject. The methods of the invention are suitable for all cancers dependent on the activity of MEX-3. In one embodiment, the p53-pathway is misregulated in the cells of the cancer. Example of such a misregulation are mutations, amplifications or overexpression of the p53 gene. In one embodiment, the cancer is a cancer of the colon, a breast cancer, or a cancer of the pancreas. In some embodiments, the cancer is treated by inhibiting/reducing metastasis formation.

The present invention also encompasses a siRNA decreasing or silencing the expression of MEX-3 or an antibody specifically binding to MEX-3 for use as a medicament to treat cancer. Alternatively, the antibody can inhibit the interaction between of MEX-3 and one of its partners.
The present invention also provides methods of screening for agents able to modulate the expression of MEX-3 expression and/or biological activity, which method comprises: (i) contacting a MEX-3 polypeptide or a fragment thereof having the biological activity of MEX-3, a polynucleotide encoding such a polypeptide or polypeptide fragment, an expression vector comprising such a polynucleotide or a cell comprising such an expression vector, and a test substance under conditions that in the absence of the test substance would permit MEX-3 expression and/or biological activity; and (ii) determining the amount of MEX-3 expression and/or biological activity, to determine whether the test substance modulates MEX-3 biological activity and/or expression, wherein a test substance which modulates MEX-3 biological activity and/or expression is a potential therapeutical agent to treat cancer. An example of the biological activity of MEX-3 is its interaction with p21, p27 and/or p57.

In addition, the present invention also encompasses a method of diagnosing cancer comprising the step of assessing the level of expression of MEX-3 in a sample from a subject. These and other aspects of the present invention should be apparent to those skilled in the art, from the teachings herein.

Brief Description of the Drawings

The following drawings are illustrative of embodiments of the invention and are not meant to limit the scope of the invention as encompassed by the claims.

Figure 1: C. elegans MEX-3 acts as an oncogene and interacts genetically with CKI-2.

As previously reported (Kadyk and Kimble, 1998, Development 125:1803-1813), C. elegans gld-1;glp-1 germ cells proliferate to form a germ cell tumor (left panel). The present inventors found that MEX-3 is required for this proliferation, since introduction of a mutation in MEX-3 suppresses the tumor (central panel). They also found that proliferation can be restored by additional mutation of CKI-2 (right panel), indicating an interaction between MEX-3 and CKI-2. Scale bar: 20 μm. Germlines are indicated with a dotted line.

Figure 2: C. elegans CKI-2 belongs to the CIP/KIP family of cell cycle inhibitors.

CKI-2 is a member of the CIP/KIP family of cell cycle inhibitors. It is equally close to each of the vertebrate members of the family, p21, p27, and p57, since it clusters with either p21 (A) or p57 (B) depending on the organism. Phylogenograms were generated with ClustalW from the protein sequences as available on the ensembl Database (human, zebrafish), flybase (drosophila), wormbase (CKI-1), or own unpublished data (CKI-2).

Figure 3: MEX-3 prevents expression of the cki-2 mRNA.

While CKI-2 is not expressed in gld-1, glp-1;glp-1 germ line tumors, it gets expressed in MEX-3 (RNAi), gld-1, glp-2;glp-1 germ line tumors, indicating that MEX-3 prevents expression of CKI-2. Also, formation of a germ line tumor is prevented by CKI-2 expression (as indicated by the size of the top and bottom gonads).

Figure 4: MEX-3 associates with cki-2 mRNA.
MEX-3 was immunoprecipitated from worm extract, and associated mRNAs were quantified with qPCR. While control genes actin, tubulin and RNA polymerase I, as well as the other CIP/KIP member of C.elegans, cki-1, are not enriched over the control immunoprecipitation, cki-2 mRNA is associated with MEX-3. The yolk receptor rme-2 and the somatic determinant pal-1, that are known to be regulated by MEX-3, serve as positive controls.

**Figure 5:** MEX-3 expression levels are associated with cancer, cancer progression and exposure to cancerogenic substances.

Database searches indicated that adverse outcome or progression of cancer correlates with higher expression of the putative oncogene MEX-3. Moreover, exposure to some carcinogens induces MEX-3 expression. Without wishing to be bound by theory, this upregulation might contribute to lower expression of cell cycle inhibitors in both situations. For example, MEX-3 expression is increased in prostate cancer tissue compared to normal tissue.

**Detailed Description of the Invention**

In their *C. elegans-based* experimental model, the present inventors surprisingly found that MEX-3 interacts with the mRNA encoding CKI-2 and regulates expression of the CKI-2 protein. MEX-3 is conserved in mammalian and the mammalian homologues of CKI-2 are p21, p27 and p57, which are well-known tumour suppressors. Without wishing to be bound by theory, the inventors hypothesized that in human a sequestration of the tumour suppressors p21, p27 and/or p57 by any of MEX-3A/B/C/D could be important in cancer. Searches in different databases indicated that, indeed, MEX-3 is up-regulated in cancerous tissues and that the administering of cancerinogens also up-regulates MEX-3 expression.

The present invention hence provides a method for treating cancer in a subject by modulating MEX-3 via the administration of a therapeutically effective amount of a modulator of MEX-3 to said subject. In some embodiments, MEX-3 is modulated by an inhibitor, such as an antibody. Alternatively, the inhibitor decreases or silences the expression of MEX-3, and is for instance a siRNA. In some embodiments, the subject is a mammal, for instance a human subject.

The methods of the invention are suitable for all cancers dependent on the activity of MEX-3. In one embodiment, the p53-pathway is misregulated in the cells of the cancer. Example of such a misregulation are mutations, amplifications or overexpression of the p53 gene. In one embodiment, the cancer is a cancer of the colon, a breast cancer, or a cancer of the pancreas. In some embodiments, the cancer is treated by inhibiting/reducing metastasis formation.

The present invention also encompasses a siRNA decreasing or silencing the expression of MEX-3 or an antibody specifically binding to MEX-3 for use as a medicament to treat cancer. Alternatively, the antibody can inhibit the interaction between of MEX-3 and one of its partners.
The present invention also provides methods of screening for agents able to modulate the expression of MEX-3 expression and/or biological activity, which method comprises: (i) contacting a MEX-3 polypeptide or a fragment thereof having the biological activity of MEX-3, a polynucleotide encoding such a polypeptide or polypeptide fragment, an expression vector comprising such a polynucleotide or a cell comprising such an expression vector, and a test substance under conditions that in the absence of the test substance would permit MEX-3 expression and/or biological activity; and (ii) determining the amount of MEX-3 expression and/or biological activity, to determine whether the test substance modulates MEX-3 biological activity and/or expression, wherein a test substance which modulates MEX-3 biological activity and/or expression is a potential therapeutical agent to treat cancer. An example of the biological activity of MEX-3 is its interaction with p21, p27 and/or p57. Moreover, the present invention also encompasses the modulators of the expression of MEX-3 expression and/or of its biological activity identified using a method of screening of the invention. In addition, the present invention also encompasses a method of diagnosing cancer comprising the step of assessing the level of expression of MEX-3 in a sample from a subject. These and other aspects of the present invention should be apparent to those skilled in the art, from the teachings herein.

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include \emph{in vivo} or \emph{in vitro} RNA transcripts of the DNA molecules of the present invention. However, a nucleic acid contained in a clone that is a member of a library (e.g., a genomic or cDNA library) that has not been isolated from other members of the library (e.g., in the form of a homogeneous solution containing the clone and other members of the library) or a chromosome removed from a cell or a cell lysate (e.g., a "chromosome spread", as in a karyotype), or a preparation of randomly sheared genomic DNA or a preparation of genomic DNA cut with one or more restriction enzymes is not "isolated" for the purposes of this invention. As discussed further herein, isolated nucleic acid molecules according to the present invention may be produced naturally, recombinantly, or synthetically.
In the present invention, a "secreted" protein refers to a protein capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as a protein released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

"Polynucleotides" can be composed of single-and double-stranded DNA, DNA that is a mixture of single-and double-stranded regions, single-and double-stranded RNA, and RNA that is mixture of single-and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single-and double-stranded regions. In addition, polynucleotides can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. Polynucleotides may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms. The expression "polynucleotide encoding a polypeptide" encompasses a polynucleotide which includes only coding sequence for the polypeptide as well as a polynucleotide which includes additional coding and/or non-coding sequence.

"Stringent hybridization conditions" refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in O.lx SSC at about 50 degree C. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, moderately high stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH2P04; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 µg/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC). Variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

The terms "fragment," "derivative" and "analog" when referring to polypeptides means polypeptides which either retain substantially the same biological function or activity as such polypeptides. An
analog includes a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature polypeptide.

The term "gene" means the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region "leader and trailer" as well as intervening sequences (introns) between individual coding segments (exons).

Polypeptides can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in the polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include, but are not limited to, acetylation, acylation, biotinylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinsitol, cross-linking, cyclization, denatization by known protecting/blocking groups, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, linkage to an antibody molecule or other cellular ligand, methylation, myristoylation, oxidation, pegylation, proteolytic processing (e.g., cleavage), phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS-STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1:2 (1983); Seifert et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

A polypeptide fragment "having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of the original polypeptide, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the original polypeptide (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, in some
embodiments, not more than about tenfold less activity, or not more than about three-fold less activity relative to the original polypeptide.)

Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for the desired homologue. "Variant" refers to a polynucleotide or polypeptide differing from the original polynucleotide or polypeptide, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the original polynucleotide or polypeptide.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Blosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=−1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter. If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score. For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 impaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a
100 base query sequence. This time the deletions are internal deletions so that there are no bases on
the 5’ or 3’ of the subject sequence which are not matched/aligned with the query. In this case the
percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5’ and 3’ of
the subject sequence which are not matched/aligned with the query sequence are manually corrected
for.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query
amino acid sequence of the present invention, it is intended that the amino acid sequence of the
subject polypeptide is identical to the query sequence except that the subject polypeptide sequence
may include up to five amino acid alterations per each 100 amino acids of the query amino acid
sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95%
identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject
sequence may be inserted, deleted, or substituted with another amino acid. These alterations of the
reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid
sequence or anywhere between those terminal positions, interspersed either individually among
residues in the reference sequence or in one or more contiguous groups within the reference
sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 92%, 95%, 96%,
97%, 98%, 99%, or 100% identical to, for instance, the amino acid sequences shown in a sequence or
to the amino acid sequence encoded by deposited DNA clone can be determined conventionally using
known computer programs. A preferred method for determining, the best overall match between a
query sequence (a sequence of the present invention) and a subject sequence, also referred to as a
global sequence alignment, can be determined using the FASTDB computer program based on the
algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query
and subject sequences are either both nucleotide sequences or both amino acid sequences. The
result of said global sequence alignment is in percent identity. Preferred parameters used in a
FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining
Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap
Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid
sequence, whichever is shorter. If the subject sequence is shorter than the query sequence due to N-
or C-terminal deletions, not because of internal deletions, a manual correction must be made to the
results. This is because the FASTDB program does not account for N-and C-terminal truncations of
the subject sequence when calculating global percent identity. For subject sequences truncated at the
N-and C-termini, relative to the query sequence, the percent identity is corrected by calculating the
number of residues of the query sequence that are N-and C-terminal of the subject sequence, which
are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the
query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB
sequence alignment. This percentage is then subtracted from the percent identity, calculated by the
above FASTDB program using the specified parameters, to arrive at a final percent identity score. This
final percent identity score is what is used for the purposes of the present invention. Only residues to
the N-and C-termini of the subject sequence, which are not matched/aligned with the query sequence,
are considered for the purposes of manually adjusting the percent identity score. That is, only query
residue positions outside the farthest N-and C-terminal residues of the subject sequence. Only residue
positions outside the N-and C-terminal ends of the subject sequence, as displayed in the FASTDB
alignment, which are not matched/aligned with the query sequence are manually corrected for. No
other manual corrections are to be made for the purposes of the present invention.

Naturally occurring protein variants are called "allelic variants," and refer to one of several alternate
forms of a gene occupying a given locus on a chromosome of an organism. (Genes 11, Lewin, B., ed.,
John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide
and/or polypeptide level. Alternatively, non-naturally occurring variants may be produced by
mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be
generated to improve or alter the characteristics of polypeptides. For instance, one or more amino
cacids can be deleted from the N-terminus or C-terminus of a secreted protein without substantial loss
of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988 (1993), reported
variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal
amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting
8-10 amino acid residues from the carboxy terminus of this protein (Dobeli et al., J. Biotechnology
7:199-216 (1988)). Moreover, ample evidence demonstrates that variants often retain a biological
activity similar to that of the naturally occurring protein. For example, Gayle and co-workers (J. Biol.
They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5
amino acid changes per variant over the entire length of the molecule. Multiple mutations were
examined at every possible amino acid position. The investigators found that "[most of the molecule
could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only
23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced
a protein that significantly differed in activity from wild-type. Furthermore, even if deleting one or more
amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one
or more biological functions, other biological activities may still be retained. For example, the ability of
a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be
retained when less than the majority of the residues of the secreted form are removed from the N-
 terminus or C-terminus. Whether a particular polypeptide lacking N-or C-terminal residues of a protein
retains such immunogenic activities can readily be determined by routine methods described herein
and otherwise known in the art.

In one embodiment where one is assaying for the ability to bind or compete with full-length MEX-3
polypeptide for binding to MEX-3 antibody, various immunoassays known in the art can be used,
including but not limited to, competitive and non-competitive assay systems using techniques such as
radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination, assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and Immuno-electrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody.

In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

Assays described herein and otherwise known in the art may routinely be applied to measure the ability of MEX-3 polypeptides and fragments, variants derivatives and analogs thereof to elicit MEX-3-related biological activity (either in vitro or in vivo) and/or to assess whether MEX-3 is present in a given sample, e.g. a sample isolated from a patient.

The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, in some embodiments, a mammal, for instance in a human. In an embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies described infra. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross-reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.


As one of skill in the art will appreciate, and as discussed above, polypeptides comprising an immunogenic or antigenic epitope can be fused to other polypeptide sequences. For example, polypeptides may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof), or albumin (including but not limited to recombinant albumin (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998)), resulting in chimeric polypeptides. Such fusion proteins may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4-
polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., Nature, 331:84-86 (1988).

Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion disulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., J. Biochem., 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, Proc. Natl. Acad. Sci. USA 88:8972-897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein.

Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni²⁺ nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers. Additional fusion proteins may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson, et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308-13 (1998).

Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-id) antibodies (including, e.g., anti-id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule.

In addition, in the context of the present invention, the term "antibody" shall also encompass alternative molecules having the same function, e.g. aptamers and/or CDRs grafted onto alternative peptidic or non-peptidic frames.
In some embodiments, the antibodies are human antigen-binding antibody fragments and include, but are not limited to, Fab, Fab' and F(ab')2, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. In some embodiments, the antibodies are human, murine (e.g., mouse and rat), donkey, ship rabbit, goat, guinea pig, camel, shark, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al. The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multi-simplicity. Multispecific antibodies may be specific for different epitopes of a polypeptide or may be specific for both a polypeptide as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol. 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, by size in contiguous amino acid residues.

Antibodies may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described herein) to a polypeptide are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide are also included in the present invention. Antibodies may also be described or specified in terms of their binding affinity to a polypeptide. Antibodies may act as agonists or antagonists of the recognized polypeptides. The invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signalling) may be determined by techniques described herein or
otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or of one of its down-stream substrates by immunoprecipitation followed by western blot analysis (for example, as described supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.


As discussed in more detail below, the antibodies may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N-or C-terminus or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Patent No. 5,314,995; and EP 396, 387.

The antibodies as defined for the present invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of-interest can be produced by various procedures well known in
the art. For example, a polypeptide of the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the antigen.

Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvurn. Such adjuvants are also well known in the art.

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: Monoclonal Antibodies and T-Cell Hybridomas 563-681 (Elsevier, N.Y., 1981). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')2 fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')2 fragments). F(ab')2 fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.

For example, the antibodies can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Immunol. Methods 184:177-186 (1995); Kettleborough et al., Eur. J. Immunol. 24:952-958 (1994); Persic et al., Gene 187:9-18 (1997); Burton et al., Advances in Immunology 57:191-280 (1994); PCT application
As described in these references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab′ and F(ab′)2 fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax, et al., BioTechniques 12(6):864-869 (1992); and Sawai et al., AJRI 34:26-34 (1995); and Better et al., Science 240:1041-1043 (1988).

Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., Methods in Enzymology 203:46-88 (1991); Shu et al., PNAS 90:7995-7999 (1993); and Skerra et al., Science 240:1038-1040 (1988). For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Gillies et al., (1989) J. Immunol. Methods 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567 and 4,816,697. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, and/or improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modelling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988).) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592, 106; EP 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska, et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332). Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences.

Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harboured by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, Int. Rev. Immunol. 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,614,318; 5,885,793; 5,916,771; and 5,939,598. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., Bio/technology 12:899-903 (1988)).

Furthermore, antibodies can be utilized to generate anti-idiotype antibodies that "mimic" polypeptides using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, FASEB J. 7(5):437-444; (1989) and Nissinoff, J. Immunol. 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens.
to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide and/or to bind its ligands/receptors, and thereby block its biological activity.

Polynucleotides encoding antibodies, comprising a nucleotide sequence encoding an antibody are also encompassed. These polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., BioTechniques 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

The amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well known in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and in some embodiments, human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a listing of human framework regions). In some embodiments, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide. In some embodiments, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, in some embodiments, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present description and within the skill of the art.

In addition, techniques developed for the production of “chimeric antibodies” (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli may also be used (Skerra et al., Science 242: 1038-1041 (1988)). The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, in some embodiments, at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, in some embodiments, at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide).

Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety, for instance to increase their therapeutic activity. The conjugates can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, a interferon, B-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF-alpha, TNF-beta, AIM I (See, International Publication No. WO 97/33899), AIM 11 (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi et al., Int. Immunol., 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors. Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Amon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs in Cancer Therapy", in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies ’84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev. 62:119-58 (1982).

Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980. The present invention is also directed to antibody-based therapies which involve administering antibodies of the invention to an animal, in some embodiments, a mammal, for example a human, patient to treat cancer. Therapeutic compounds include, but are not limited to, antibodies (including
fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

The invention also provides methods for treating cancer in a subject by inhibiting MEX-3 by administration to the subject of an effective amount of an inhibitory compound or pharmaceutical composition comprising such inhibitory compound. In some embodiments, said inhibitory compound is an antibody or an siRNA. In an embodiment, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is in some embodiments, an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is in some embodiments, a mammal, for example human.

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

Various delivery systems are known and can be used to administer a compound, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, Science 249: 1527-1 533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid.) In yet another embodiment, the
compound or composition can be delivered in a controlled release system. In one embodiment, a
pump may be used (see Langer, supra; Sefton, CRC Crit. Ref, Biomed. Eng. 14:201 (1987); Buchwald
et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321 :574 (1989)). In another embodiment,
polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise
(eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design
and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J.,
embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the
brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications
of Controlled Release, supra, vol. 2, pp. 115-138 (1984)).
Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533
(1990)).
The present invention also provides pharmaceutical compositions for use in the treatment of cancer by
inhibiting a MEX-3. Such compositions comprise a therapeutically effective amount of an inhibitory
compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term
"pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state
government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in
animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or
vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids,
such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as
peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the
pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and
glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable
pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk,
silica gel, sodium stearate, glycerol monostearate, tallow, sodium chloride, dried skim milk, glycerol,
propylene glycol, water, and ethanol and the like. The composition, if desired, can also contain minor
amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the
form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release
formulations and the like. The composition can be formulated as a suppository, with traditional binders
and carriers such as triglycerides. Oral formulation can include standard carriers such as
pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine,
cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in
"Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a
therapeutically effective amount of the compound, in some embodiments, in purified form, together
with a suitable amount of carrier so as to provide the form for proper administration to the patient. The
formulation should suit the mode of administration.
In an embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anaesthetic such as lidocaine to ease pain at the site of the injection.

Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically scaled container such as an ampoule or sachette indicating the quantity of active agent.

Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The compounds of the invention can be formulated as neutral or salt forms.

Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc. The amount of the compound which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances.

Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. In some embodiments, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, for example 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

Also encompassed is a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the
manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by
the agency of manufacture, use or sale for human administration.
The antibodies as encompassed herein may also be chemically modified derivatives which may
provide additional advantages such as increased solubility, stability and circulating time of the
polypeptide, or decreased immunogenicity (see U. S. Patent No. 4,179,337). The chemical moieties
for derivatisation may be selected from water soluble polymers such as polyethylene glycol, ethylene
glycol/propylene glycol copolymers, carboxymethyl cellulose, dextran, polyvinyl alcohol and the like.
The antibodies may be modified at random positions within the molecule, or at predetermined
positions within the molecule and may include one, two, three or more attached chemical moieties.
The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene
glycol, the preferred molecular weight is between about 1 kDa and about 100000 kDa (the term
"about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some
less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be
used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the
effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other
known effects of the polyethylene glycol to a therapeutic protein or analog). For example, the
polyethylene glycol may have an average molecular weight of about 200, 500, 1000, 1500, 2000,
2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000,
10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000,
16,500, 17,600, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000,
50,000, 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000, 90,000, 95,000, or 100,000 kDa. As
noted above, the polyethylene glycol may have a branched structure. Branched polyethylene glycols
are described, for example, in U. S. Patent No. 5,643, 575; Morpurgo et al., Appl. Biochem.
Biotechnol. 56:59-72 (1996); Vorobjev et al., Nucleosides Nucleotides 18:2745-2750 (1999); and
Caliceti et al., Bioconjug. Chem. 10:638-646 (1999). The polyethylene glycol molecules (or other
chemical moieties) should be attached to the protein with consideration of effects on functional or
antigenic domains of the protein. There are a number of attachment methods available to those skilled
in the art, e.g., EP 0 401 384 (coupling PEG to G-CSF), see also Malik et al., Exp. Hematol. 20:1028-
1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol
may be covalently bound through amino acid residues via a reactive group, such as, a free amino or
carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be
bound. The amino acid residues having a free amino group may include lysine residues and the N-
terminus amino acid residues; those having a free carboxyl group may include aspartic acid residues
glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as
a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is
attachment at an amino group, such as attachment at the N-terminus or lysine group. As suggested
above, polyethylene glycol may be attached to proteins via linkage to any of a number of amino acid
residues. For example, polyethylene glycol can be linked to proteins via covalent bonds to lysine,
histidine, aspartic acid, glutamic acid, or cysteine residues. One or more reaction chemistries may be employed to attach polyethylene glycol to specific amino acid residues (e.g., lysine, histidine, aspartic acid, glutamic acid, or cysteine) of the protein or to more than one type of amino acid residue (e.g., lysine, histidine, aspartic acid, glutamic acid, cysteine and combinations thereof) of the protein. As indicated above, pegylation of the proteins of the invention may be accomplished by any number of means. For example, polyethylene glycol may be attached to the protein either directly or by an intervening linker. Linkerless systems for attaching polyethylene glycol to proteins are described in Delgado et al., Crit. Rev. Thera. Drug Carrier Sys. 9:249-304 (1992); Francis et al., Intern. J. of Hematol. 68:1-18 (1998); U.S. Patent No. 4,002,53 1; U.S. Patent No. 5,349,052; WO 95/06058; and WO 98/32466.

By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains the polypeptide of the present invention or mRNA. As indicated, biological samples include body fluids (such as semen, lymph, sera, plasma, urine, synovial fluid and spinal fluid) which contain the polypeptide of the present invention, and other tissue sources found to express the polypeptide of the present invention. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

"RNAi" is the process of sequence specific post-transcriptional gene silencing in animals and plants. It uses small interfering RNA molecules (siRNA) that are double-stranded and homologous in sequence to the silenced (target) gene. Hence, sequence specific binding of the siRNA molecule with mRNAs produced by transcription of the target gene allows very specific targeted 'knockdown' of gene expression.

"siRNA" or "small-interfering ribonucleic acid" according to the invention has the meanings known in the art, including the following aspects. The siRNA consists of two strands of ribonucleotides which hybridize along a complementary region under physiological conditions. The strands are normally separate. Because of the two strands have separate roles in a cell, one strand is called the "anti-sense" strand, also known as the "guide" sequence, and is used in the functioning RISC complex to guide it to the correct mRNA for cleavage. This use of "anti-sense", because it relates to an RNA compound, is different from the antisense target DNA compounds referred to elsewhere in this specification. The other strand is known as the "anti-guide" sequence and because it contains the same sequence of nucleotides as the target sequence, it is also known as the sense strand. The strands may be joined by a molecular linker in certain embodiments. The individual ribonucleotides may be unmodified naturally occurring ribonucleotides, unmodified naturally occurring deoxyribonucleotides or they may be chemically modified or synthetic as described elsewhere herein. In some embodiments, the siRNA molecule is substantially identical with at least a region of the coding sequence of the target gene to enable down-regulation of the gene. In some embodiments, the degree of identity between the sequence of the siRNA molecule and the targeted region of the gene is at least
60% sequence identity, in some embodiments at least 75% sequence identity, for instance at least 85% identity, 90% identity, at least 95% identity, at least 97%, or at least 99% identity.

Calculation of percentage identities between different amino acid/polypeptide/nucleic acid sequences may be carried out as follows. A multiple alignment is first generated by the ClustalX program (pairwise parameters: gap opening 10.0, gap extension 0.1, protein matrix Gonnet 250, DNA matrix IUB; multiple parameters: gap opening 10.0, gap extension 0.2, delay divergent sequences 30%, DNA transition weight 0.5, negative matrix off, protein matrix gonnet series, DNA weight IUB; Protein gap parameters, residue-specific penalties on, hydrophilic penalties on, hydrophilic residues GPSNDQERK, gap separation distance 4, end gap separation off). The percentage identity is then calculated from the multiple alignment as \((N/T)^\ast\) 100, where \(N\) is the number of positions at which the two sequences share an identical residue, and \(T\) is the total number of positions compared.

Alternatively, percentage identity can be calculated as \((N/S)^\ast\) 100 where \(S\) is the length of the shorter sequence being compared. The amino acid/polypeptide/nucleic acid sequences may be synthesised de novo, or may be native amino acid/polypeptide/nucleic acid sequence, or a derivative thereof. A substantially similar nucleotide sequence will be encoded by a sequence which hybridizes to any of the nucleic acid sequences referred to herein or their complements under stringent conditions. By stringent conditions, we mean the nucleotide hybrids to filter-bound DNA or RNA in 6x sodium chloride/sodium citrate (SSC) at approximately 45°C followed by at least one wash in 0.2x SSC/0.1% SDS at approximately 5-65°C. Alternatively, a substantially similar polypeptide may differ by at least 1, but less than 5, 10, 20, 50 or 100 amino acids from the peptide sequences according to the present invention. Due to the degeneracy of the genetic code, it is clear that any nucleic acid sequence could be varied or changed without substantially affecting the sequence of the protein encoded thereby, to provide a functional variant thereof. Suitable nucleotide variants are those having a sequence altered by the substitution of different codons that encode the same amino acid within the sequence, thus producing a silent change. Other suitable variants are those having homologous nucleotide sequences but comprising all, or portions of, sequences which are altered by the substitution of different codons that encode an amino acid with a side chain of similar biophysical properties to the amino acid it substitutes, to produce a conservative change. For example small non-polar, hydrophobic amino acids include glycine, alanine, leucine, isoleucine, valine, proline, and methionine; large non-polar, hydrophobic amino acids include phenylalanine, tryptophan and tyrosine; the polar neutral amino acids include serine, threonine, cysteine, asparagine and glutamine; the positively charged (basic) amino acids include lysine, arginine and histidine; and the negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

The accurate alignment of protein or DNA sequences is a complex process, which has been investigated in detail by a number of researchers. Of particular importance is the trade-off between optimal matching of sequences and the introduction of gaps to obtain such a match. In the case of proteins, the means by which matches are scored is also of significance. The family of PAM matrices (e.g., Dayhoff, M. et al., 1978, Atlas of protein sequence and structure, Natl. Biomed. Res. Found.)
and BLOSUM matrices quantify the nature and likelihood of conservative substitutions and are used in multiple alignment algorithms, although other, equally applicable matrices will be known to those skilled in the art. The popular multiple alignment program ClustalW, and its windows version ClustalX (Thompson et al., 1994, Nucleic Acids Research, 22, 4673-4680; Thompson et al., 1997, Nucleic Acids Research, 24, 4876-4882) are efficient ways to generate multiple alignments of proteins and DNA.

Frequently, automatically generated alignments require manual alignment, exploiting the trained user's knowledge of the protein family being studied, e.g., biological knowledge of key conserved sites. One such alignment editor programs is Align (http://www.gwdg.de/dhepper/download/; Hepperle, D., 2001: Multicolor Sequence Alignment Editor. Institute of Freshwater Ecology and Inland Fisheries, 16775 Stechlin, Germany), although others, such as JalView or Cinema are also suitable.

Calculation of percentage identities between proteins occurs during the generation of multiple alignments by Clustal. However, these values need to be recalculated if the alignment has been manually improved, or for the deliberate comparison of two sequences. Programs that calculate this value for pairs of protein sequences within an alignment include PROTDIST within the PHYLIP phylogeny package (Felsenstein; http://evolution.gs.washington.edu/phylip.html) using the "Similarity Table" option as the model for amino acid substitution (P). For DNA/RNA, an identical option exists within the DNADIST program of PHYLIP.

The dsRNA molecules in accordance with the present invention comprise a double-stranded region which is substantially identical to a region of the mRNA of the target gene. A region with 100% identity to the corresponding sequence of the target gene is suitable. This state is referred to as "fully complementary". However, the region may also contain one, two or three mismatches as compared to the corresponding region of the target gene, depending on the length of the region of the mRNA that is targeted, and as such may be not fully complementary. In an embodiment, the RNA molecules of the present invention specifically target one given gene. In order to only target the desired mRNA, the siRNA reagent may have 100% homology to the target mRNA and at least 2 mismatched nucleotides to all other genes present in the cell or organism. Methods to analyze and identify siRNAs with sufficient sequence identity in order to effectively inhibit expression of a specific target sequence are known in the art. Sequence identity may be optimized by sequence comparison and alignment algorithms known in the art (see Gribskov and Devereux, Sequence Analysis Primer, Stockton Press, 1991, and references cited therein) and calculating the percent difference between the nucleotide sequences by, for example, the Smith-Waterman algorithm as implemented in the BESTFIT software program using default parameters (e.g., University of Wisconsin Genetic Computing Group).

The length of the region of the siRNA complementary to the target, in accordance with the present invention, may be from 10 to 100 nucleotides, 12 to 25 nucleotides, 14 to 22 nucleotides or 15, 16, 17 or 18 nucleotides. Where there are mismatches to the corresponding target region, the length of the complementary region is generally required to be somewhat longer. In an embodiment, the inhibitor is a siRNA molecule and comprises between approximately 5bp and 50 bp, in some embodiments,
between 10 bp and 35 bp, or between 15 bp and 30 bp, for instance between 18 bp and 25 bp. In some embodiments, the siRNA molecule comprises more than 20 and less than 23 bp. Because the siRNA may carry overhanging ends (which may or may not be complementary to the target), or additional nucleotides complementary to itself but not the target gene, the total length of each separate strand of siRNA may be 10 to 100 nucleotides, 15 to 49 nucleotides, 17 to 30 nucleotides or 19 to 25 nucleotides.

The phrase "each strand is 49 nucleotides or less" means the total number of consecutive nucleotides in the strand, including all modified or unmodified nucleotides, but not including any chemical moieties which may be added to the 3' or 5' end of the strand. Short chemical moieties inserted into the strand are not counted, but a chemical linker designed to join two separate strands is not considered to create consecutive nucleotides.

The phrase "a 1 to 6 nucleotide overhang on at least one of the 5' end or 3' end" refers to the architecture of the complementary siRNA that forms from two separate strands under physiological conditions. If the terminal nucleotides are part of the double-stranded region of the siRNA, the siRNA is considered blunt ended. If one or more nucleotides are unpaired on an end, an overhang is created. The overhang length is measured by the number of overhanging nucleotides. The overhanging nucleotides can be either on the 5' end or 3' end of either strand.

The siRNA according to the present invention display a high in vivo stability and may be particularly suitable for oral delivery by including at least one modified nucleotide in at least one of the strands. Thus the siRNA according to the present invention contains at least one modified or non-natural ribonucleotide. A lengthy description of many known chemical modifications are set out in published PCT patent application WO 200370918. Suitable modifications for delivery include chemical modifications can be selected from among: a) a 3' cap; b) a 5' cap, c) a modified internucleoside linkage; or d) a modified sugar or base moiety.

Suitable modifications include, but are not limited to modifications to the sugar moiety (i.e. the 2' position of the sugar moiety, such as for instance 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., Helv. Chim. Acta, 1995, 78, 486-504) i.e., an alkoxylalkoxy group) or the base moiety (i.e. a non-natural or modified base which maintains ability to pair with another specific base in an alternate nucleotide chain). Other modifications include so-called 'backbone' modifications including, but not limited to, replacing the phosphoester group (connecting adjacent ribonucleotides) with for instance phosphorothioates, chiral phosphorothioates or phosphorodithioates.

End modifications sometimes referred to herein as 3' caps or 5' caps may be of significance. Caps may consist of simply adding additional nucleotides, such as "T-T" which has been found to confer stability on a siRNA. Caps may consist of more complex chemistries which are known to those skilled in the art.

Design of a suitable siRNA molecule is a complicated process, and involves very carefully analysing the sequence of the target mRNA molecule. On exemplary method for the design of siRNA is illustrated in WO2005/059132. Then, using considerable inventive endeavour, the inventors have to
choose a defined sequence of siRNA which has a certain composition of nucleotide bases, which would have the required affinity and also stability to cause the RNA interference.

The siRNA molecule may be either synthesised de novo, or produced by a micro-organism. For example, the siRNA molecule may be produced by bacteria, for example, E. coli. Methods for the synthesis of siRNA, including siRNA containing at least one modified or non-natural ribonucleotides are well known and readily available to those of skill in the art. For example, a variety of synthetic chemistries are set out in published PCT patent applications WO2005021749 and WO200370918. The reaction may be carried out in solution or, in some embodiments, on solid phase or by using polymer supported reagents, followed by combining the synthesized RNA strands under conditions, wherein a siRNA molecule is formed, which is capable of mediating RNAi.

It should be appreciated that siNAs (small interfering nucleic acids) may comprise uracil (siRNA) or thymidine (siDNA). Accordingly the nucleotides U and T, as referred to above, may be interchanged. However it is preferred that siRNA is used.

Gene-silencing molecules, i.e. inhibitors, used according to the invention are in some embodiments, nucleic acids (e.g. siRNA or antisense or ribozymes). Such molecules may (but not necessarily) be ones, which become incorporated in the DNA of cells of the subject being treated. Undifferentiated cells may be stably transformed with the gene-silencing molecule leading to the production of genetically modified daughter cells (in which case regulation of expression in the subject may be required, e.g. with specific transcription factors, or gene activators).

The gene-silencing molecule may be either synthesised de novo, and introduced in sufficient amounts to induce gene-silencing (e.g. by RNA interference) in the target cell. Alternatively, the molecule may be produced by a micro-organism, for example, E. coli, and then introduced in sufficient amounts to induce gene silencing in the target cell.

The molecule may be produced by a vector harbouring a nucleic acid that encodes the gene-silencing sequence. The vector may comprise elements capable of controlling and/or enhancing expression of the nucleic acid. The vector may be a recombinant vector. The vector may for example comprise plasmid, cosmid, phage, or virus DNA. In addition to, or instead of using the vector to synthesise the gene-silencing molecule, the vector may be used as a delivery system for transforming a target cell with the gene silencing sequence.

The recombinant vector may also include other functional elements. For instance, recombinant vectors can be designed such that the vector will autonomously replicate in the target cell. In this case, elements that induce nucleic acid replication may be required in the recombinant vector. Alternatively, the recombinant vector may be designed such that the vector and recombinant nucleic acid molecule integrates into the genome of a target cell. In this case nucleic acid sequences, which favour targeted integration (e.g. by homologous recombination) are desirable. Recombinant vectors may also have DNA coding for genes that may be used as selectable markers in the cloning process.

The recombinant vector may also comprise a promoter or regulator or enhancer to control expression of the nucleic acid as required. Tissue specific promoter/enhancer elements may be used to regulate
expression of the nucleic acid in specific cell types, for example, endothelial cells. The promoter may be constitutive or inducible.

Alternatively, the gene silencing molecule may be administered to a target cell or tissue in a subject with or without it being incorporated in a vector. For instance, the molecule may be incorporated within a liposome or virus particle (e.g. a retrovirus, herpes virus, pox virus, vaccinia virus, adenovirus, lentivirus and the like).

Alternatively a "naked" siRNA or antisense molecule may be inserted into a subject's cells by a suitable means e.g. direct endocytic uptake.

The gene silencing molecule may also be transferred to the cells of a subject to be treated by either transfection, infection, microinjection, cell fusion, protoplast fusion or ballistic bombardment. For example, transfer may be by: ballistic transfection with coated gold particles; liposomes containing a siNA molecule; viral vectors comprising a gene silencing sequence or means of providing direct nucleic acid uptake (e.g. endocytosis) by application of the gene silencing molecule directly.

In an embodiment of the present invention siNA molecules may be delivered to a target cell (whether in a vector or "naked") and may then rely upon the host cell to be replicated and thereby reach therapeutically effective levels. When this is the case the siNA is in some embodiments, incorporated in an expression cassette that will enable the siNA to be transcribed in the cell and then interfere with translation (by inducing destruction of the endogenous mRNA coding the targeted gene product).

Inhibitors according to any embodiment of the present invention may be used in a monotherapy (e.g. use of siRNAs alone). However it will be appreciated that the inhibitors may be used as an adjunct, or in combination with other therapies.

The inhibitors of MEX-3 may be contained within compositions having a number of different forms depending, in particular on the manner in which the composition is to be used. Thus, for example, the composition may be in the form of a capsule, liquid, ointment, cream, gel, hydrogel, aerosol, spray, micelle, transdermal patch, liposome or any other suitable form that may be administered to a person or animal. It will be appreciated that the vehicle of the composition of the invention should be one which is well tolerated by the subject to whom it is given, and in some embodiments, enables delivery of the inhibitor to the target site.

The inhibitors of MEX-3 may be used in a number of ways.

For instance, systemic administration may be required in which case the compound may be contained within a composition that may, for example, be administered by injection into the blood stream.

Injections may be intravenous (bolus or infusion), subcutaneous, intramuscular or a direct injection into the target tissue (e.g. an intraventricular injection-when used in the brain). The inhibitors may also be administered by inhalation (e.g. intranasally) or even orally (if appropriate).

The inhibitors of the invention may also be incorporated within a slow or delayed release device. Such devices may, for example, be inserted at the site of a tumour, and the molecule may be released over weeks or months. Such devices may be particularly advantageous when long term treatment with an
inhibitor of MEX-3 is required and which would normally require frequent administration (e.g. at least daily injection).

It will be appreciated that the amount of an inhibitor that is required is determined by its biological activity and bioavailability which in turn depends on the mode of administration, the physicochemical properties of the molecule employed and whether it is being used as a monotherapy or in a combined therapy. The frequency of administration will also be influenced by the above-mentioned factors and particularly the half-life of the inhibitor within the subject being treated.

Optimal dosages to be administered may be determined by those skilled in the art, and will vary with the particular inhibitor in use, the strength of the preparation, and the mode of administration. Additional factors depending on the particular subject being treated will result in a need to adjust dosages, including subject age, weight, gender, diet, and time of administration. When the inhibitor is a nucleic acid conventional molecular biology techniques (vector transfer, liposome transfer, ballistic bombardment etc) may be used to deliver the inhibitor to the target tissue. Known procedures, such as those conventionally employed by the pharmaceutical industry (e.g. in vivo experimentation, clinical trials, etc.), may be used to establish specific formulations for use according to the invention and precise therapeutic regimes (such as daily doses of the gene silencing molecule and the frequency of administration). Generally, a daily dose of between 0.01 µg/kg of body weight and 0.5 g/kg of body weight of an inhibitor of MEX-3 may be used for the treatment of cancer in the subject, depending upon which specific inhibitor is used. When the inhibitor is an siRNA molecule, the daily dose may be between 1 pg/kg of body weight and 100 mg/kg of body weight, in some embodiments, between approximately 10 pg/kg and 10 mg/kg, or between about 50 pg/kg and 1mg/kg. When the inhibitor (e.g. siRNA) is delivered to a cell, daily doses may be given as a single administration (e.g. a single daily injection). Various assays are known in the art to test dsRNA for its ability to mediate RNAi (see for instance Elbashir et al., Methods 26 (2002), 199-213). The effect of the dsRNA according to the present invention on gene expression will typically result in expression of the target gene being inhibited by at least 10%, 33%, 50%, 90%, 95% or 99% when compared to a cell not treated with the RNA molecules according to the present invention. Similarly, various assays are well-known in the art to test antibodies for their ability to inhibit the biological activity of their specific targets. The effect of the use of an antibody according to the present invention will typically result in biological activity of their specific target being inhibited by at least 10%, 33%, 50%, 90%, 95% or 99% when compared to a control not treated with the antibody.

The term "cancer" refers to a group of diseases in which cells are aggressive (grow and divide without respect to normal limits), invasive (invade and destroy adjacent tissues), and sometimes metastatic (spread to other locations in the body). These three malignant properties of cancers differentiate them from benign tumors, which are self-limited in their growth and don't invade or metastasize (although some benign tumor types are capable of becoming malignant). A particular type of cancer is a cancer forming solid tumours. Such cancer forming solid tumours can be breast cancer, prostate carcinoma or oral squamous carcinoma. Other cancer forming solid tumours for which the methods and inhibitors of
the invention would be well suited can be selected from the group consisting of adrenal cortical cancers, angiomyoid fibrous histiocytomas (AFH), squamous cell bladder carcinomas, urothelial carcinomas, bone tumours, e.g. adamantinomas, aneurysmal bone cysts, chondroblastomas, chordomas, chondromyxoid fibromas, chondrosarcomas, fibrous dysplasias of the bone, giant cell tumours, osteochondromas or osteosarcomas, breast tumours, e.g. secretory ductal carcinomas, chordomas, clear cell hidradenomas of the skin (CCH), colorectal adenocarcinomas, carcinomas of the gallbladder and extrahepatic bile ducts, combined hepatocellular and cholangiocarcinomas, fibrogenesis imperfecta ossium, pleomorphic salivary gland adenomas head and neck squamous cell carcinomas, chromophobe renal cell carcinomas, clear cell renal cell carcinomas, nephroblastomas (Wilms tumor), papillary renal cell carcinomas, primary renal ASPSCR1 - TFE3 t(X:17)(p1 1;q25) tumors, renal cell carcinomas, laryngeal squamous cell carcinomas, liver adenomas, hepatoblastomas, hepatocellular carcinomas, non-small cell lung carcinomas, small cell lung cancers, malignant melanoma of soft parts, medulloblastomas, meningiomas, neuroblastomas, astrocytic tumours, ependymomas, peripheral nerve sheath tumours, neuroendocrine tumours, e.g. phaeochromocytomas, neurofibromas, oral squamous cell carcinomas, ovarian tumours, e.g. epithelial ovarian tumours, germ cell tumours or sex cord-stromal tumours, pericytomas, pituitary adenomas, posterior uveal melanomas, rhabdoid tumours, skin melanomas, cutaneous benign fibrous histiocytomas, intravenous leiomyomatosis, aggressive angiomyxomas, liposarcomas, myxoid liposarcomas, low grade fibromyxoid sarcomas, soft tissue leiomyosarcomas, biphasic synovial sarcomas, soft tissue chordomas, alveolar soft part sarcomas, clear cell sarcomas, desmoplastic small round cell tumours, elastofibromas, Ewing's tumours, extraskeletal myxoid chondrosarcomas, inflammatory myofibroblastic tumours, lipoblastomas, lipoma, benign lipomatous tumours, liposarcomas, malignant lipomatous tumours, malignant myoepitheliomas, rhabdomyosarcomas, synovial sarcomas, squamous cell cancers, subungual exostosis, germ cell tumours in the testis, spermatocytic seminomas, anaplastic (undifferentiated) carcinomas, oncocytic tumours, papillary carcinomas, carcinomas of the cervix, endometrial carcinomas, leiomyoma as well as vulva and/or vagina tumours. In an embodiment of the invention, the cancer is a colon cancer, a breast cancer, or a cancer of the pancreas.

As used herein, the term "metastasis" refers to the spread of cancer cells from one organ or body part to another area of the body, i.e. to the formation of metastases. This movement of tumor growth, i.e. metastasis or the formation of metastases, occurs as cancer cells break off the original tumor and spread e.g. by way of the blood or lymph system. Without wishing to be bound by theory, metastasis is an active process and involves an active breaking from the original tumor, for instance by protease digestion of membranes and or cellular matrices, transport to another site of the body, for instance in the blood circulation or in the lymphatic system, and active implantation at said other area of the body.

In one embodiment, the cancer is a MEX-3-dependent cancer. MEX-3-dependent cancers are cancers where MEX-3 has become an essential gene. MEX-3-dependent cancers can be easily identified by
depleting the cells of MEX-3 expression, and identifying the cancers that are not able to grow, migrate or forming metastases in the absence of it.

The present invention also provides a method of screening compounds to identify those which might be useful for treating cancer in a subject by inhibiting MEX-3 as well as the so-identified compounds. MEX-3 encodes two KH domain-containing RNA binding proteins. In the early embryo, maternally provided MEX-3 is required for specifying the identities of the anterior AB blastomere and its descendants, as well as for the identity of the P3 blastomere and proper segregation of the germline P granules. MEX-3 mRNA is distributed uniformly in the syncytial core of the adult distal gonad, mature oocytes, and early 1-cell stage embryos, but then becomes more prominent in the AB blastomere and its daughters by the 4-cell stage after which it is rapidly degraded save for the D and P4 blastomeres. MEX-3 protein is also detected uniformly in the cytoplasm of oocytes and 1-cell stage embryos, but like the mRNA, becomes more abundant in AB and its daughters at the 2- and 4-cell stages, respectively, before disappearing; MEX-3 is also detected in association with P granules from the 2-cell stage until the late stages of embryogenesis. There are four MEX-3 genes in human: mex3a, mex3B, mex3C and mex3D. Mex3a (SEQ ID NO:1) is also known as MEX-3A, RKHD4, MEX3A protein, RING finger and KH domain-containing protein, MEX-3 homolog A (C. elegans), ring finger and KH domain containing 4, and ring finger and KH domain containing protein. Mex3B (SEQ ID NO:2) is also known as DKFZp434J061 7, KIAA0209, MEX-3B, MGC17199, RKHD3, RNF195, RING finger and KH domain-containing protein 3, RING finger protein 195, MEX-3 homolog B, MEX-3 homolog B (C. elegans), and ring finger and KH domain containing 3. Mex3C (SEQ ID NO:3) is also known as BM-013, FLJ38871, MEX-3C, RKHD2, RNF194, RING finger and KH domain-containing protein, RING finger protein 1943, MEX-3 homolog C (C. elegans), and ring finger and KH domain containing 2. Mex3D (SEQ ID NO:4) is also known as KIAA2031, MEX-3D, MEX3, OK/SW-cl.4, RKHD1, RNF193, TINO, Tino 1, RING finger and KH domain-containing protein 1, RING finger protein 193, bcl-2 ARE RNA binding protein, MEX-3 homolog D (C. elegans), ring finger (C3HC4 type) and KH domain containing and ring finger 1 and KH domain containing 1.

Cyclin-dependent kinase inhibitor 1A (p21, Cip1), also known as CDKN1A, is a protein which in humans is encoded by the CDKN1A gene located on chromosome 6 (6p21.2). This gene encodes a potent cyclin-dependent kinase inhibitor (CKI). The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation. Two alternatively spliced variants, which encode an identical protein, have been reported. p21 is a CKI that directly inhibits the activity of cyclin-CDK2 and cyclin-CDK4 complexes. p21
functions as a regulator of cell cycle progression at S phase. The expression of p21 is controlled by
the tumor suppressor protein p53. Sometimes, it is expressed without being induced by P53. This kind
of induction plays a big role in p53 independent apoptosis by p21. Expression of p21 is mainly
dependent on two factors 1) stimulus provided 2) type of the cell. The function of this gene relates in
part to stress response. p21 is the major transcriptional target of the tumor suppressor gene, p53;
despite this, loss-of-function mutations in p21 (unlike p53) do not accumulate in cancer nor do they
dispose to cancer incidence. In fact, mice genetically engineered to lack p21 develop rather
normally and are not susceptible to cancer at a higher rate than the norm (again, unlike p53). p21 also
mediates the resistance of hematopoietic cells to an infection with HIV by complexing with the HIV
integrase and thereby aborting chromosomal integration of the provirus.

Cyclin-dependent kinase inhibitor 1B (p27, Kip1), also known as CDKN1B, is a human gene. It
encodes a protein which belongs to the Cip/Kip family of cyclin dependent kinase (Cdk) inhibitor
proteins. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4
complexes, and thus controls the cell cycle progression at G1. It is often referred to as a cell cycle
inhibitor protein because its major function is to stop or slow down the cell division cycle. The p27Kip1
gene has a DNA sequence similar to other members of the "Cip/Kip" family which include the
p21 Cip1/Waf1 and p57Kip2 genes. In addition to this structural similarity the "Cip/Kip" proteins share
the functional characteristic of being able to bind several different classes of Cyclin and Cdk
molecules. For example, p27Kip1 binds to cyclin D either alone, or when complexed to its catalytic
subunit CDK4. In doing so p27Kip1 inhibits the catalytic activity of Cdk4, which means that it prevents
Cdk4 from adding phosphate residues to its principal substrate, the retinoblastoma (pRb) protein.

Increased levels of the p27Kip1 protein typically cause cells to arrest in the G1 phase of the cell cycle.
Likewise, p27Kip1 is able to bind other Cdk proteins when complexed to cyclin subunits such as Cyclin
E/Cdk2 and Cyclin A/Cdk2. In general, extracellular growth factors which prevent cell growth cause an
increase in p27Kip1 levels inside a cell. For example, levels of p27Kip1 increase when Transforming
Growth Factor β (TGF β) is present outside of epithelial cells causing a growth arrest. In contrast
interleukin 2 (IL-2) causes p27Kip1 levels to drop in T-lymphocytes. A mutation of this gene may lead
to loss of control over the cell cycle leading to uncontrolled cellular proliferation.

Cyclin-dependent kinase inhibitor 1C (p57, Kip2), also known as CDKN1C, is protein which in humans
is encoded by the CDKN1C imprinted gene. Cyclin-dependent kinase inhibitor 1C is a tight-binding
inhibitor of several G1 cyclin/Cdk complexes and a negative regulator of cell proliferation. Mutations of
CDKN1C are implicated in sporadic cancers and Beckwith-Wiedemann syndrome suggesting that it is
a tumor suppressor candidate. CDKN1C is a tumor suppressor human gene on chromosome 11
(11p15) and belongs to the cip/kip gene family. It encodes a cell cycle inhibitor that binds to G1 cyclin-
CDK complexes. Thus p57KIP2 causes arrest of the cell cycle in G1 phase. A mutation of this gene
may lead to loss of control over the cell cycle leading to uncontrolled cellular proliferation. p57KIP2
has been associated with Beckwith-Wiedemann syndrome (BWS) which is characterized by increased
risk of tumor formation in childhood.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Examples

Materials and Methods

Nematode culture Standard procedures were used to maintain the N2 strain of C. elegans. Typically, worms grown at 20 °C were bleached to collect eggs, the larvae were synchronized by starvation (on plates), and allowed to feed at 25 °C, unless indicated otherwise. The gld-1 dsRNA-expressing vector was generated in this study and contains the sequence corresponding to aa 131-305 of GLD-1 (WormBase release 156).

Mutant strains: The following strains were described previously: pie-1::MEX-3::GFP (Jud et al, 2008) The following strains were generated in this study: mex-3 (or20) gld-2(q497) gld-1 (q485); unc-32(e1 89) glp-1 (q175)/hT2 (qls48; pharyngeal GFP); integrated myo-3::YFP (Fire vector L4671, pPD1 33.63); mex-3(or20) gld-1 (q485) gld-2(q497); cki-2(ok21 05); unc-32(e1 89) glp-1 (175)f

ClustalW alignments Protein sequences were used as available on the ensembl database (human, zebrafish), wormbase (CKI-1, CKI-2 long) or as determined based on 3' RACE (CKI-2 short). Trees were constructed with the online tool ClustalW (http://www.ebi.ac.uk/Tools/clustalw2/index.html) using default parameters.

3' RACE 3' RACE was essentially performed as previously described, except that no second nested primer pair was used (Scotto-Lavino et al, 2006,3' End cDNA amplification using classic RACE, Nat Protoc. 2006; 1(6):2742-5).

Immune-localization Primary antibodies used are HIM-3 (Zetka et al., 1999) and CKI-2 (Feng et al., 1999). Secondary antibodies were goat anti-mouse alexa-488 and anti-rabbit alexa-488 (Molecular Probes). For CKI-2 immunostainings, gonads were prepared essentially as described previously (Ciosk et al., 2004). For HIM-3 staining, gonads were dissected in phosphate-buffered saline (PBS), frozen on dry ice, fixed first in 100% methanol (-20 °C) for 5min, and then in 3.7 % paraformaldehyde, PBS, 0.08 M HEPES, 1.6 mM MgS04, 0.8 mM EGTA, pH 6.9 at room temperature (RT) for 5min.

Fluorescence and DIC images were captured with a Zeiss ImagerZ1 microscope equipped with an AxioCAMMRm (Zeiss). Unless indicated otherwise, images were acquired with the same exposure and processed in Adobe Photoshop CS2 in an identical manner.

MEX-3 associates with the cki-2 mRNA MEX-3::GFP or wild-type (N2) worms were grown on gld-i(RNAi) to increase expression of the transgene and harvested as young adults. Antibodies used for immunoprecipitation, mouse anti-GFP (Roche), mouse anti-FLAG M2 (Sigma), or mouse anti-Myc
were pre-bound to protein A sepharose CL-4B (GE Healthcare Bio-Sciences) in extraction buffer (50 mM Hepes pH 7.4, 100 mM KOAc, 5 mM MgAc, 0.1 % Triton X-1 00, 10 % Glycerol (w/v), 20 mM β-glycerophosphate, 3 mg ml-1 complete EDTA-free protease inhibitor cocktail (Roche). For protein extraction, the buffer was supplemented with 2 mM DTT, Pepstatin A, 1 mM Phenylmethyl sulfonflyluoride, 200 u ml-1 RNAsin (Promega) and the concentration of the protease inhibitor cocktail was increased to 7 mg ml-1. Worms were homogenized with Dounce homogenizer. 700 µg of a pre-cleared extract (input) was subjected to immunoprecipitation. The immunoprecipitates were washed 3 times with extraction buffer.

RNA was extracted from beads using TRIzol (Invitrogen). Precipitation efficiency was enhanced by addition of 10 µg total RNA from mouse brain (Stratagene) to each sample. RT-PCR quantification of co-immunoprecipitated mRNAs cDNAs were generated using random hexamers with the superscript II reverse transcriptase system (Invitrogen) from ¼ th of each IP and 2.5 µg of each input. Real time PCR was performed in duplicate upon 1/20th of obtained IP cDNA using Absolute QPCR SYBR green ROX mix (AbGene) on an ABI PRISM 7700 system (Applied Biosystems). PCR reactions were performed with an initial activation step of 15 min at 95 °C, then 40 cycles of 20 sec at 95 °C and 60 sec at 60 °C. Standard curves for quantification were generated from a serial dilution of input cDNA for each primer pair. The amount of target present in each IP was derived from the standard curve, an average calculated for the duplicates and then corrected by the corresponding input value. The fold enrichment in each MEX-3 IP was calculated relative to the control IP.

Results

C.elegans MEX-3 acts as an oncogene and interacts genetically with CKI-2. As previously reported (Kadyk and Kimble, 1998, Development 125: 1803-1813), C.elegans gld-1 gld-2; glp-1 germ cells proliferate to form a germ cell tumor (Fig. 1, left panel). MEX-3 is required for this proliferation, since introduction of a mutation in MEX-3 suppresses the tumor (Fig. 1, central panel). Proliferation can be restored by additional mutation of CKI-2 (Fig. 1, right panel), indicating an interaction between MEX-3 and CKI-2.

C.elegans CKI-2 belongs to the CIP/KIP family of cell cycle inhibitors. CKI-2 is a member of the CIP/KIP family of cell cycle inhibitors, of which C.elegans has two members (CKI-1 and CKI-2). It is equally close to each of the vertebrate members of the family, p21; p27; and p57, since it clusters with either p21 (A) or p57 (B) depending on the vertebrate organism. While CKI-2 is not expressed in gld-1, gld-2; glp-1germline tumors, it gets expressed in MEX-3(RNAi), gld-1, gld-2; glp-1germline tumors, indicating that MEX-3 prevents expression of CKI-2. Also, formation of a germ line tumor is prevented by CKI-2 expression. MEX-3 was immunoprecipitated from worm extract, and associated mRNAs were quantified with qPCR. While control genes actin, tubulin and RNA polymerase II, as well as the other CIP/KIP member of C.elegans, cki-1, are not enriched over the control immunoprecipitation, cki-2 mRNA is associated with MEX-3. The yolk receptor rme-2 and the somatic determinant pal-1, that
are known to be regulated by MEX-3, serve as positive controls. Database searches indicated that adverse outcome or progression of cancer correlates with higher expression of the putative oncogene MEX-3. Moreover, exposure to some carcinogens induces MEX-3 expression. Without wishing to be bound by theory, this upregulation might contribute to lower expression of cell cycle inhibitors in both situations.

**CKI-2 is orthologous to vertebrate tumor suppressors of the CIP/KIP family CKI-1 and CKI-2 are, by protein sequence similarity, members of the CIP/KIP family of cell cycle inhibitors. Also, loss of CKI-1 results in overproliferation of embryonic cells and embryonic lethality. CKI-2 has so far not been implicated in any vital process in C.elegans. When CKI-1 and CKI-2 are aligned with the various isoforms of human CIP/KIP proteins, they show highest similarity with human p57 (Figure 2, top panel). However, in a comparison with both zebrafish and human sequences, CKI-1 and CKI-2 cluster with p21 (Figure 2, bottom panel). Therefore, CKI-1 and CKI-2 can be considered similarly close or distant to any one of the vertebrate family members.**

**CKI-2 interacts genetically with MEX-3 and is responsible for the MEX-3 germline phenotype MEX-3 is required for germ line stem cell fate and stem-cell like proliferation in the triple mutant background *gld-1, gld-2; glp-1*. Removing MEX-3 from this background causes germline stem cells to exit mitosis, and initiate differentiation towards mature gametes. This effect is mediated by CKI-2, since additional removal of CKI-2 rescues stem cell proliferation and stem cell fate. This is consistent with the idea that MEX-3 might be downregulating CKI-2 expression, which in turn would be instrumental for the maintenance of stem cell proliferation and fate.

**CKI-2 expression is prevented by MEX-3 Indeed, *gld-1 gld-2; glp-1* germ cells respond with expression of CKI-2 to removal of MEX-3 by RNAi, as assayed by immunostainings.**

**MEX-3 interacts with the CKI-2 mRNA** Since MEX-3 is an RNA-binding KH-domain protein that has been implicated in mRNA regulation before, we investigated whether MEX-3 might regulate cki-2 mRNA by directly associating with the 3'UTR. RNA-Co-IPs were performed on a transgenic line carrying MEX-3::GFP. Associated mRNAs were analysed by qPCR, using two known targets of MEX-3 as positive control and several housekeeping genes as negative controls. CKI-2 was enriched over control IP to a similar extent as known MEX-3 targets, indicating direct or indirect interaction of the cki-2 mRNA with the MEX-3 protein.

**MEX-3 might function as an oncogene also in human cancers** GEO profile searches for MEX-3 confirmed that MEX-3 is higher expressed in certain tumors or cancerogenic situations compared to controls. For example, MEX-3 expression is increased in prostate cancer tissue compared to normal tissue, as well as in metastases compared to the primary tumor. Furthermore, MEX-3 is induced in pulmonary artery endothelial cells HPAEC exposed to ultrafine particles for 4 hours and large airway epithelial cells of phenotypically normal smokers express higher levels of MEX-3 than those of non-smokers.
Claims

1. A method for treating cancer in a subject by modulating MEX-3 by administering to said subject a therapeutically effective amount of a modulator of MEX-3.

2. The method of claim 1 wherein MEX-3 is modulated by an inhibitor.

3. The method of claims 1 or 2 wherein the inhibitor is an antibody.

4. The method of claims 1 or 2 wherein the inhibitor decreases or silences the expression of MEX-3.

5. The method of claim 4 wherein the inhibitor is a siRNA.

6. The method of any of claims 1 to 5 wherein the subject is a mammal, for instance a human subject.

7. The method of any of claims 1 to 6 wherein the p53-pathway is misregulated in the cells of the cancer.

8. The method of any of claims 1 to 7 wherein the cancer is a cancer of the colon, a breast cancer or a cancer of the pancreas.

9. The method of any of claims 1 to 8 wherein the modulation of MEX-3 reduces metastasis formation.

10. A siRNA decreasing or silencing MEX-3, for use as a medicament to treat cancer.

11. An antibody specifically binding to MEX-3, for use as a medicament to treat cancer.

12. The antibody of claim 9, wherein said antibody inhibits the interaction between MEX-3 and p21, p27 and/or p57.

13. The siRNA of claim 10 or the antibody of claim 11 or 12, wherein the p53-pathway is misregulated in the cells of the cancer, or wherein said cancer is a cancer of the colon, a breast cancer or a cancer of the pancreas.
14. A method for the identification of a substance that modulates the expression of MEX-3 and/or biological activity, which method comprises:
   (i) contacting a MEX-3 polypeptide or a fragment thereof having the biological activity of MEX-3, a polynucleotide encoding such a polypeptide or polypeptide fragment, an expression vector comprising such a polynucleotide or a cell comprising such an expression vector, and a test substance under conditions that in the absence of the test substance would permit MEX-3 expression and/or biological activity; and
   (ii) determining the amount of MEX-3 expression and/or biological activity, to determine whether the test substance modulates MEX-3 biological activity and/or expression, wherein a test substance which modulates MEX-3 biological activity and/or expression is a potential therapeutical agent to treat cancer.

15. A method of diagnosing cancer comprising the step of assessing the level of expression of MEX-3 in a sample from a subject.
Figure 5

(disease state)

<table>
<thead>
<tr>
<th>Disease State</th>
<th>(single channel) count</th>
<th>percentile rank within the sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burden</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metastatic</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Figures and diagrams should be described or explained in detail here for natural text.)
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07K16/18 C12N15/11 C12Q1/68 G01N33/50 A61P35/04

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC.

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07K C12N C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, CHEM ABS Data, COMPENDEX, MEDLINE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 99/32619 A1 (CARNEGIE INST OF WASHINGTON [US]; UNIV MASSACHUSETTS [US]; FIRE ANDREW) 1 July 1999 (1999-07-01) page 31, line 23 - page 14, line 11</td>
<td>1,6-9,14</td>
</tr>
<tr>
<td>X</td>
<td>TAKADA HITOMI ET AL: &quot;The RNA-binding protein Mex3b has a fine-tuning system for mRNA regulation in early Xenopus development&quot; DEVELOPMENT (CAMBRIDGE), vol. 136, no. 14, July 2009 (2009-07), pages 2413-2422, XP002567134 page 2417, col umn 2, line 25 - page 2418, col umn 2, line 19</td>
<td>1,6-9, 14</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:

• "A" document defining the general state of the art which is not considered to be of particular relevance.
• "E" earlier document but published on or after the international filing date.
• "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified).
• "O" document referring to an oral disclosure, use, exhibition or other means.
• "P" document published prior to the international filing date but later than the priority date claimed.

• "R" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention.
• "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone.
• "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
• "Z" document member of the same patent family.

Date of the actual completion of the international search: 20 October 2010

Date of mailing of the international search report: 03/11/2010

Name and mailing address of the ISA:

European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Hilversum Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016

Authorized officer: Pilling, Stephen
### DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>Wo 9932619</td>
<td>01-07-1999</td>
<td>AU 743798 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 1938099 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2311999 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1042462 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2002516062 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2009291209 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6506559 Bi</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2003056235 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2003051263 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2003055020 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2008248576 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2009077679 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2003167490 Al</td>
</tr>
</tbody>
</table>

Form PCT/ISA/210 (patent family annex) (April 2005)